tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Fellermann K et al. Tacrolimus: a new immunosuppressant for steroid refractory inflammatory bowel disease. 2001 Transplant. Proc. pmid:11377517
Salizzoni M et al. Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation. 2001 Transplant. Proc. pmid:11377521
Langrehr JM et al. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563. 2001 Transplant. Proc. pmid:11377531
Migita K and Eguchi K FK 506-mediated T-cell apoptosis induction. 2001 Transplant. Proc. pmid:11377532
Nakache R et al. Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization. 2001 Transplant. Proc. pmid:11377533
Nakatani T et al. Effect of tacrolimus on the gene expression of renin and endothelin in the rat kidney. 2001 Transplant. Proc. pmid:11377534
Schweizer RT and Meisterling LD Tolerability of mycophenolate mofetil in organ transplant recipients. 2001 Transplant. Proc. pmid:11377540
Langrehr JM et al. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial. 2001 Transplant. Proc. pmid:11377549
Nagashima N et al. Immunocompetence assay for net effect of combined immunosuppression. 2001 Transplant. Proc. pmid:11377556
Chariat MN et al. Basiliximab in the therapy of acute rejection after organ transplantation. 2001 Transplant. Proc. pmid:11377567
Molinaro M et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. 2001 Transplant. Proc. pmid:11377570
McCarter JF et al. FK 506 protects brain tissue in animal models of stroke. 2001 Transplant. Proc. pmid:11377571
van Gelder T et al. ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications. 2001 Transplant. Proc. pmid:11377580
Sandborn WJ Transcending conventional therapies: the role of biologic and other novel therapies. 2001 Inflamm. Bowel Dis. pmid:11380043
Teixeira R et al. Management of recurrent hepatitis C after liver transplantation. 2001 J. Viral Hepat. pmid:11380792
Kooman JP et al. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. 2001 Am. J. Kidney Dis. pmid:11382685
Barten MJ et al. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. 2001 J. Immunol. Methods pmid:11384672
Wakugawa M et al. Interferon-gamma-induced RANTES production by human keratinocytes is enhanced by IL-1beta, TNF-alpha, IL-4 and IL-13 and is inhibited by dexamethasone and tacrolimus. 2001 Dermatology (Basel) pmid:11385231
Goffin E et al. Osteoporosis after organ transplantation. 2001 Lancet pmid:11386322
Boillot O et al. Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation. 2001 Clin Transplant pmid:11389705
Utsugi R et al. Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully mhc-mismatched kidney allografts in miniature swine. 2001 Transplantation pmid:11391221
Yin DP et al. Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. 2001 Transplantation pmid:11391223
Karasu Z et al. Acute tacrolimus overdose and treatment with phenytoin in liver transplant recipients. 2001 J Okla State Med Assoc pmid:11392178
Maesaki S [Molecular mechanize and clinical feature of azole-resistant Candida albicans strains and new strategy of treatment]. 2001 Jpn J Antibiot pmid:11392683
Tuteja S et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. 2001 Transplantation pmid:11397967
Otsuka M et al. Long-term results of donor-specific blood transfusion with cyclosporine in living related kidney transplantation. 2001 Nephron pmid:11399917
Bekersky I et al. Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. 2001 J Clin Pharmacol pmid:11402631
Penson MG et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. 2001 J. Heart Lung Transplant. pmid:11404165
Allen A et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. 2001 Arch Dermatol pmid:11405764
Diaz-Romero J et al. Coexpression of CD4 and CD8alpha on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs. 2001 J. Immunol. Methods pmid:11406149
Osako M et al. Alloimmune response may be involved in neointimal hyperplasia in cryopreserved aortic allografts. 2001 Transplant. Proc. pmid:11406250
Faivre L et al. FK 506 dose in transplantation: from theory to practice. 2001 Transplant. Proc. pmid:11406256
Chan KL et al. Porcine small bowel transplantation with FK506 as a single immunosuppressant. 2001 Transplant. Proc. pmid:11406260
Charpentier B An induction versus no-induction protocol in anticalcineurin-based immunosuppression using very low-dose steroids. 2001 Transplant. Proc. pmid:11406262
Weir MR Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation. 2001 Transplant. Proc. pmid:11406264
Land W et al. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. 2001 Transplant. Proc. pmid:11406265
Sakuma S et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). 2001 Int. Immunopharmacol. pmid:11407316
Shimoishi K et al. FK506 (tacrolimus) increases rat alpha1-acid glycoprotein expression in liver and primary cultured hepatocytes. 2001 Eur. J. Pharmacol. pmid:11408029
Navarro X et al. Effects of FK506 on nerve regeneration and reinnervation after graft or tube repair of long nerve gaps. 2001 Muscle Nerve pmid:11410918
Hiroi J [Pharmacological profile and clinical effect of tacrolimus ointment (Protopic ointment) for atopic dermatitis]. 2001 Nippon Yakurigaku Zasshi pmid:11411345
Kaibori M et al. FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia in rat hepatocytes. 2001 Life Sci. pmid:11411802
Sun J et al. Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration. 2001 Circulation pmid:11413088
Sing A et al. Molecular diagnosis of an Enterocytozoon bieneusi human genotype C infection in a moderately immunosuppressed human immunodeficiency virus seronegative liver-transplant recipient with severe chronic diarrhea. 2001 J. Clin. Microbiol. pmid:11414246
Kolpak S and Mehler P Medical issues in treating renal transplant patients. 2001 Hosp Pract (1995) pmid:11419536
Chang RK et al. Echocardiographic findings of hypertrophic cardiomyopathy in children after orthotopic liver transplantation. 2001 Pediatr Transplant pmid:11422821
Hasegawa T et al. Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. 2001 Pediatr Transplant pmid:11422824
Kanoh S et al. FK506 inhibits Cl- secretion in airway epithelium via calcineurin-independent mechanism. 2001 Eur. J. Pharmacol. pmid:11426833
Mourad M et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. 2001 Clin. Chem. pmid:11427455
Matsuo N et al. Tacrolimus inhibits cytokine production and chemical mediator release following antigen stimulation of passively sensitized human lung tissues. 2001 Ann. Allergy Asthma Immunol. pmid:11428741
Ramm K and Plückthun A High enzymatic activity and chaperone function are mechanistically related features of the dimeric E. coli peptidyl-prolyl-isomerase FkpA. 2001 J. Mol. Biol. pmid:11428902